Acne Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris – Drugs In Development, 2022, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.
Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 9, 21, 4, 23, 3 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.
Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AMD Therapeutics LLC
Amgen Inc
Amytrx Therapeutics Inc
Annji Pharmaceutical Co Ltd
AOBiome LLC
Arcutis Biotherapeutics Inc
Atacama Therapeutics Inc
Attillaps Holdings Inc
Avecho Biotechnology Ltd
Avicanna Inc
Bausch Health Companies Inc
Biofrontera AG
Biozeus Pharmaceutical SA
Blueberry Therapeutics Ltd
Boston Pharmaceuticals Inc
Botanix Pharmaceuticals Ltd
Boulos and Cooper Pharmaceuticals Pty Ltd
Claritas Pharmaceuticals Inc
Clinuvel Pharmaceuticals Ltd
Cosmo Pharmaceuticals NV
Cutanea Life Sciences Inc
Dermata Therapeutics Inc
Dermavant Sciences Inc
Devonian Health Group Inc
Eligo Bioscience SA
Galephar Pharmaceutical Research Inc
Hoth Therapeutics Inc
Innovation Pharmaceuticals Inc
Journey Medical Corp
Kintor Pharmaceutical Ltd
Lee's Pharmaceutical Holdings Ltd
Lipidio Pharmaceuticals Inc
Lipidor AB
Madam Therapeutics BV
Maruho Co Ltd
Matrisys Bioscience Inc
Mayne Pharma Group Ltd
Melinta Therapeutics Inc
Novabiotics Ltd
Novan Inc
Novartis AG
Ortho Dermatologics Inc
Paratek Pharmaceuticals Inc
Phagelux Inc
PHI Therapeutics Inc
Promius Pharma LLC
Provectus Biopharmaceuticals Inc
Revive Therapeutics Ltd
Riptide Bioscience Inc
Sagimet Biosciences Inc
Sanofi
SaNOtize Research and Development Corp
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Timber Pharmaceuticals Inc
Verge Therapeutics Inc
VYNE Therapeutics Inc
Vyome Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Dermatology reports